Phase II/III clinical trial of JP001 in combination with standard chemoradiotherapy in newly diagnosed GBM patients: An open label, multicenter study
Latest Information Update: 25 Aug 2021
At a glance
- Drugs Siroquine (Primary) ; Temozolomide; Trastuzumab
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors HebaBiz Biotech
- 25 Aug 2021 New trial record
- 20 Aug 2021 Results (n=6) presented in a HebaBiz Biotech media release
- 20 Aug 2021 According to a HebaBiz Biotech media release, Kwan Hwa Chi, is the principal investigator of this study